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We have examined the CD8 + peripheral T cell repertoire of C57BL/6 (H-2  b) mice for cytotoxic 
T lymphocyte (CTL) reactivities  to insulin, using in vitro immunization with a chymotryptic 
digest of reduced bovine insulin. The results presented in this study demonstrate that potentially 
autoreactive H-2Kb-restricted  cytotoxic T cells specific for an autologous insulin B chain peptide 
are present in the preimmune splenic T  cell repertoire.  The immunogenic peptide comprises 
residues  7-15 from the insulin B chain and has features in common with naturally processed 
Kb-restricted  peptides identified by others. The minimal peptide sequence recognized by these 
cytotoxic T  cells is 10-15,  which is highly conserved in mammalian species and constitutes a 
self-peptide in mice. The presence of class I major histocompatibility complex-restricted CTLs 
with potentially autoreactive specificities in preimmune animals raises the possibility of a role 
for such ceUs in autoimmune disease states. Possible mechanisms for the in vivo expansion of 
insulin peptide-specific  CTLs are discussed. 
I 
nsulin has been studied extensively by immunologists as 
a model antigen system for examining the genetic and cel- 
lular regulation of Th cell recognition in class II MHC- 
restricted cell-mediated immune responses. These investiga- 
tions have provided significant  insight into the processing 
requirements and structural constraints involved in generating 
antigenic peptide fragments in the class II MHC presenta- 
tion pathway. A number of studies have demonstrated that 
maintenance of an intact interchain disulfide linkage between 
the A and B chains is necessary for the effective Th response 
to several dominant insulin epitopes (1-5).  However, other 
investigators have shown that a class II H-2-restricted Th re- 
sponse can be induced against both insulin A chain- and in- 
sulin B chain-derived peptides in the absence of the disulfide- 
linked B  and A  chain fragments, respectively  (6-9).  It is 
tempting to speculate that the Th response to one or more 
of these insulin-derived peptides may be relevant to the patho- 
genesis  of  insulin-dependent  (type  I)  diabetes  mellitus 
(IDDM). 1 In this regard, the well-established association be- 
tween expression of certain class II MHC alleles and suscep- 
tibility to IDDM has focused the interests of immunologists 
on the possible role of class II MHC-restricted, CD4 + Th 
1Abbreviations used in  this paper: BI,  bovine insulin;  IDDM,  insulin- 
dependent diabetes mdlitus; SN, supematant; VSV N, vesicular stomatis 
virus nuclear (protein peptide). 
cells in the pathogenesis of this autoimmune state (10). Indeed, 
substantial evidence has been obtained that implicates CD4 + 
Th cell involvement as a possible autoimmune effector mech- 
anism in the progression of IDDM (11-14), although the target 
autoantigen in IDDM remains unidentified. 
Several reports, however, have suggested a similar involve- 
ment of CD8 + , class I MHC-restricted CTLs in the patho- 
genesis of IDDM (15-17).  It has also been speculated  that 
a likely target antigen for such autoimmune CTLs may be 
a self-peptide derived from processing of the insulin mole- 
cule in the class I presentation pathway (18). With our cur- 
rent understanding that class I MHC-restricted CTL responses 
also require antigen processing for effective presentation to 
CD8 + CTLs, a large effort is presently underway to more 
fully understand the processing requirements and structural 
characteristics  for antigenic peptides generated in the class 
I MHC presentation pathway. An in vitro approach designed 
to induce CTLs specific for peptides of defined sequence has 
been introduced by Bevan and cooworkers (19), whereby the 
in vitro stimulation of spleen cells with a complete tryptic 
digest of ovalbumin was employed for the induction of peptide- 
specific, CD8 + CTLs.  In the present study we have em- 
ployed a modified form of this approach to obtain class I 
H-2b-restricted,  CD8 + CTLs specific for an insulin-derived 
peptide. In addition to providing information concerning the 
structural basis for insulin peptides as antigens for class I MHC- 
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insulin peptides might contribute to our understanding  of 
the proposed involvement of CD8 + CTLs as autoimmune 
effector cells involved in the pathogenesis  of IDDM. 
One  prerequisite  for  such  a  role  for  CD8 +,  insulin 
peptide-specific CTLs is to demonstrate that such potentially 
autoreactive T  cells are present in the preimmune repertoire 
of normal animals. In this report we describe the induction 
of CD8 +,  insulin peptide-specific CTLs by in vitro stimu- 
lation of C57BL/6 (H-2  b) spleen cells with a chymotryptic 
digest of reduced bovine insulin (BI).  The characterization 
of these B6-derived CTLs indicates they are specific for an 
autologous insulin B chain peptide and further demonstrates 
the existence of such autoreactive CTLs in the spleen-derived 
mature T  cell repertoire of naive C57BL/6  mice.  Possible 
mechanisms for the maintenance of these potentially autoreac- 
tive CTLs, without any apparent detrimental effects, in the 
preimmune  repertoire are considered. 
Materials and Methods 
Animal.  All mice used in this study were originally obtained 
from either The Jackson Laboratory (Bar Harbor, ME) or Scripps 
Clinic and Research Foundation (La Jolla, CA) and have been sub- 
sequently bred and maintained in microisolator cages in our colony 
at the West Virginia University Health Sciences Center Vivarium. 
Mice were routinely used for experimental studies between 8 and 
12 wk of age. Female rats of the Lewis strain were purchased from 
Charles River Breeding Laboratories,  Inc. (Wilmington, MA) and 
used, at '~10 wk of age, for the preparation of rat spleen cell-derived 
Con A  supematant  (SN). 
Cell Lines.  All cell lines are maintained by serial passage in RP-10 
media (RPMI 1640 plus 10% heat-inactivated  FCS and 1% r-gluta- 
mine, penicillinAtreptomycin, and 5  x  10 -s M 2-ME). EL4 is a 
thymoma-derived tumor cell line from the C57BL/6 (H-2  b) mouse 
strain.  P815 is a mastocytoma-derived tumor cell line from the 
BALB/c (H-2  a) strain, and the CBA.D1 tumor cell line is derived 
from the CBA (H-2  k) strain.  The transfected cell lines, L+K  b and 
L+D  b, are derived from the LMTK- (H-2  ~) fibroblast cell line and 
were a generous gift from Dr. Stanley G. Nathenson (Albert Ein- 
stein  College of Medicine,  Bronx, NY). 
Antigens.  BI and purified A and B chains were purchased from 
Sigma Chemical Co. (St. Louis, MO). The denatured form of BI 
was prepared by incubation, with stirring overnight of a 10-mg/ml 
solution in 8 M urea plus 200 mM 2-ME in 0.1  M  Tris buffer, 
pH 8.3. Chymotryptic digestion was carried out by addition of 
5% (wt/wt) cr  (Sigma Chemical Co.) to either dena- 
tured or native insulin,  or purified A or B chain, in buffer, pH 
8.3. The digestion with chymotrypsin was allowed to proceed, with 
stirring,  for 24 h  at 37~ 
Individual HPLC-derived fractions were obtained after reverse- 
phase HPLC analysis of the whole chymotryptic digest on a semi- 
preparative C-18 (octadecylsilane) column (Vydac; The Separations 
Group, Hesperia, CA). Fractions were eluted at 2 ml/min with 
a linear gradient of 0-50% acetonitrile, over a time course of 90 
min. Peptides were synthesized as previously described (20, 21) using 
a standard manual solid-phase synthesis procedure on a polystyrene- 
co-1% divinylbenzene resin and tert-butyloxycarbonyl for all N ~- 
protection of amino adds. Couplings were carried out using N-N"- 
diisopropylcarbodiimide and were monitored by ninhydrin reaction 
(22). Simultaneous resin cleavage and side-chain deprotection was 
achieved by the high-low hydrogen fluoride method (23). The crude 
products were purified to 98% purity by reverse-phase HPLC as 
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previously described (20, 21), and peptide compositions were verified 
by amino acid analysis. 
Induction and Expansion of Insulin-specific CTLs.  Primary CTLs 
were induced by in vitro stimulation with denatured BI chymo- 
tryptic digest. Primary cultures were established by sensitizing 8-10 
x  107 spleen cells from female C57BL/6 (H-2  b) mice with 4/zM 
chymotryptic digest of reduced BI per T-25 flask in 10 ml RP-10 
media. After a 7-d incubation, the primary cultures were stimu- 
lated by mixing the primary effector cells (5  x  10  6) with 4 #M 
of the insulin chymotrypsin digest plus irradiated syngeneic feeders 
(5  x  107 C57BL/6 spleen cells irradiated with 3,000 rad) in 10 
ml RP-10 per T-25 flask. Cultures were subsequently maintained 
in 24-well plates (#2646; Costar Data Packaging, Cambridge, MA) 
by weekly stimulation of 4-5  x  10  s effector cells/well with a 
denatured insulin chymotryptic digest (4 #M) plus 5  x  106 irradi- 
ated syngeneic feeder cells in RP-10 media supplemented with 5% 
rat Con A SN and 50 mM c~-methyl mannoside. 
Analysis of Lyric Activity by SlCr-release  Assay.  The lytic activity 
of CTL cultures and clones was assayed in a 3-h SlCr-release assay. 
Briefly, this is performed as follows. Target cells are incubated in 
100 #1 vol RP-10 media plus 200 #Ci StCr per 106 cells for 60 min 
at 37~  followed by one wash in PBS. Target cells are resuspended 
in 10 mls RP-10 media and incubated an additional 30 min at 37~ 
After a final wash, target cells are resuspended  to 2  x  10  s cells/ml 
in RP-10 media, and 50 #l/weU is added to 96-well round-bottomed 
microtiter plates. Insulin digests and peptides, to be tested as poten- 
tial antigens, are resuspended to an initial concentration of 8-16 
#M in RPMI 1640 media plus 2% BSA without serum, and a 50 
#1 vol is added to each well containing SlCr-labeled target cells. 
Target cells and antigens are then incubated for 15 min at 37~ 
Effector CTL populations and clones are resuspended appropriately 
to yield the final desired effector/target ratios in RP-10 media, and 
100 #1 is added to each well as appropriate. Since the final vol in 
each well is 200 #1, the final antigen concentrations tested in this 
assay are 2-4 #M. After incubation at 37~  in 7% CO2 for 3 h, 
the assay plates  are centrifuged for 7 min. One-half the vol (100 
#1) is collected from each well and transferred to 6  x  50-mm tubes 
for determination of total 51Cr counts on an Clinigamma counter 
(model 1272; LKB Instruments, Turku, Finland).  Background ra- 
dioactivity is determined by collecting supernatants from wells in 
which RP-10 media was used in place of effector CTLs. Maximum 
count determinations are obtained from wells to which 100 ~1 of 
Triton X-100 was added in place of effector CTLs. The determina- 
tion of specific lysis for these samples is calculated  according to 
the formula: %  specific lysis  =  100  x  (experimental release  - 
background release/maximum release  -  background release). 
Peptide Competition Assay.  Truncated peptides,  which do not 
target lysis by insulin-specific  CTLs, were examined in a peptide 
competition assay to determine if their addition in a SlCr-release 
assay inhibits CTbmediated lysis directed against the target anti- 
genic peptide. Briefly, this procedure is conducted as follows:  A 
constant excess amount of truncated peptide (10 #M) is added to 
5tCr-labeled target cells. Then titrated quantities  of the target pep- 
tide, ranging from 4 #M-5 nM, are added to appropriate wells. 
After a 15-min incubation ofpeptides and target cells, CTL effector 
cells are added to give the appropriate E/T ratios,  and the assay 
is allowed to proceed by incubation at 37~  for 3 h. Percent specific 
lysis is calculated  as described above for determination of lytic ac- 
tivity. 
Results 
Induction and Initial Characterization of Insulin Peptide-specific 
Cytotoxic  T  Lymphocytes.  A  modification of the approach 
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Figure 1.  Reactivity of bulk population ofC57BL/6-derived CTLs in- 
duced by in vitro sensitization with a chymotryptic digest of bovine in- 
sulin. (A) Response directed against syngeneic EL4 (H-2  b) targets in the 
presence of 4 #M (0) chymotryptic  digest of denatured bovine insulin, 
(11) chymotryptic digest of undenatured insulin, (A) native insulin, and 
(O) no antigen. (B) Reactivity against allogeneic I)815 (H-2  a) targets with 
antigens as indicated above. 
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Figure 2.  Responses  of bulk population of 
B6-derived CTLs against EL4 targets in the 
presence of (e -  -  -  e) 4 #M denatured 
insulin chymotryptic digest; (11 -  -  -  II) 
4 #M insulin B chain digest; (A -  -  -  A) 
4  #M  denatured  A  chain  digest;  and 
(O-----O) no antigen. 
described by Carbone et al. (19), to induce peptide-specific 
CTLs by in vitro peptide stimulation with an enzymatic di- 
gest of purified protein, was employed to produce insulin 
peptide-specific CTLs. Spleen cells from C57BL/6 (H-2  b) fe- 
male mice were used to establish primary (1 ~  ) in vitro cul- 
tures by stimulation with a complete 5% (wt/wt) chymo- 
tryptic digest of denatured BI.  Briefly, 8-10  x  107 spleen 
cells were incubated in 10 ml RP-10 with a 4 #M concentra- 
tion of the chymotryptic denatured BI digest. After 5 d in 
culture, the primary CTL effector cells frequently demon- 
strated only minimal antigen-specific  reactivity (data  not 
shown). After several passages of in vitro restimulation all 
cultures consistently exhibited a significant  antigen-specific 
CTL response against syngeneic H-2  b target cells. The re- 
sults shown in Fig. 1 A demonstrate that C57BL/6-derived 
CTLs lyse syngeneic EL4 (H-2  b) target cells in the presence 
of a 4-#M concentration of denatured BI chymotryptic di- 
gest, but not in the presence of the same concentration of 
native BI. 
A response of much lower magnitude is observed in the 
presence of undenatured BI chymotryptic digest, suggesting 
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that the chymotryptic fragment generated by digestion of 
denatured insulin may include one of the cysteine residues 
involved in the interchain disulfide bonds between the A and 
B chains. Alternatively, it is possible that the single intrachain 
disulfide bond between residues A6 and All in the A chain 
must be disrupted to achieve maximum CTL responsiveness 
of a chymotryptic fragment from the A chain. To distinguish 
between these possibilities,  we tested chymotryptic digests 
of purified insulin B chain and purified, reduced A chain as 
antigens for targeting the lytic response of the insulin pep- 
tide CTLs against EL4 target cells. The results shown in Fig. 
2 demonstrate that the B6-derived CTL response is directed 
against a fragment(s) from the insulin B chain chymotryptic 
digest. Furthermore, the absence of any CTL activity against 
the chymotryptic digest of reduced insulin A chain indicates 
that the CTL response is specific  only for a B chain fragment(s). 
Although H-2b-restricted, insulin digest-specific CTLs re- 
spond in an antigen-specific manner on syngeneic target cells, 
they also exhibit an alloreactive response on allogeneic P815 
(H-2  a) target cells, demonstrating significant lysis in the ab- 
sence of insulin chymotryptic peptides which is unaltered by 
the addition of specific antigen (Fig. 1 B). All clones derived 
from this CTL population also exhibit this dual reactivity 
(data not shown), indicating that each CTL in this popula- 
tion possesses  both antigen-specific and aUoreactive  specificities. 
Dual-reactive  T cells, which recognize allogeneic MHC in 
the absence of foreign antigen, in addition to syngeneic MHC 
plus foreign antigen, have been previously described for both 
class II-restricted T cells (24, 25) and class I-restricted CTLs 
(26,  27).  In addition, "promiscuous CTLs" which recog- 
nize foreign antigen in the context of a variety of class I MHC 
alleles have been isolated (19, 28, 29). The insulin peptide- 
specific CTLs described  here are unresponsive against the 
H-2Lexpressing target cells, CBA.D1 and LMTK-, even in 
the presence of antigen (data not shown). Furthermore, class I 
MHC-restricted peptide recognition by the insulin-specific 
CTLs occurs only in the context of syngeneic H-2  b target 
cells. Thus the functional reactivity of these CTLs is similar 
to other dual-reactive,  antigen-specific  T cells that, in addi- 
tion to their primary specificity, exhibit an additional alloreac- 
tivity, which in this case is directed against target cells ex- 
pressing allogeneic  H-2  a class I molecules. At the present 
time, the precise nature of the H-2  d class I specificity of this 
alloreactive response is undetermined. 
Identification of Insulin B  Chain Peptide as the  Target An- 
tigen.  To determine the primary sequence of the insulin B 
chain chymotryptic fragment which constitutes the target 
antigen for these CTLs, we performed a preparative HPLC 
analysis on 10 mg of the insulin B chain chymotryptic di- 
gest. The HPLC profile shown in Fig. 3 A  reveals that 11 
major  discrete  peaks,  presumably representing individual 
chymotryptic fragments, could be separated in this digest prep- 
aration. Each peak was recovered as an individual fraction 
for use as a potential antigen for targeting the CTL-mediated 
lysis against  syngeneic EL4  target  cells. Fractions  were 
resuspended to the same molar concentration found in the 
complete digest preparation for analysis of antigenic activity. 
Thus, all fractions were tested at a final 4 #M equivalent con- 2  4  5  9  10  11 
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Figure 3.  (A) Preparative  HPLC profile of purified insulin B chain 
chymotryptic digest, showing 11 fractions collected  individually for anal- 
ysis for antigenic reactivity. (B) Response  of CTL clone 10.5.4 (30:1 E/T 
ratio) against 4/~M equivalent concentration of the 11 HPLC fractions, 
and against denatured insulin digest and insulin B chain digest on EL4 
targets. 
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Figure 4.  Clone 10.5.4 response 
against 4/~M (O -  -  -  e) denatured 
insulin digest; (O-------O)  insulin 
B  chain  peptide,  p7-15;  and 
(A  A) no antigen. 
centration in a 3-h 51Cr-release assay. The results shown in 
Fig. 3 B reveal the lytic response for one of several representa- 
tive cloned CTL lines isolated from these B6-derived CTLs, 
designated  clone  10.5.4,  and  depict  the  antigenic  activity 
present in each fraction represented in Fig. 3 A,  as well as 
the corresponding activity in the presence of chymotryptic 
digests of denatured insulin and insulin B chain.  It is dear 
from these results that all of the antigenic reactivity in the 
insulin B chain chymotryptic digest resides in fraction  10. 
The results from amino acid composition analysis of fraction 
10 were compared with the primary sequence of the insulin 
B chain. Accordingly, a single chymotryptic fragment, cor- 
responding to the B chain peptide p7-15, was identified in 
this fraction. The primary sequence of this peptide is: Cys- 
Gly-Ser-His-Leu-Val-Glu-Ala-Leu, derived by chymotryptic 
cleavage on the carboxyl-side of the leucine residues at posi- 
tions 6 and  15 of the B chain.  To confirm  that  this nine- 
Beef 
Mouse  1 
Mouse  II 
Insulin A  Chain 
1  21 
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......... D .......... T-----I  .................................. 
Insulin  B Chain 
1  7  15  30 
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Mouse II  .... K .....................................................  M-S 
Figure 5.  Comparison  of primary sequences  for A and B chains from 
bovine insulin, and murine I and murine II insulin. 
residue B chain peptide constitutes the target antigen, a pep- 
tide corresponding  to the above sequence was synthesized 
and tested for its reactivity with clone 10.5.4 on EL4 target 
cells. As shown in Fig. 4, the response to this synthetic pep- 
tide is similar to that seen against the chymotryptic digest 
of the denatured insulin preparation, thus confirming the in- 
sulin  B chain  peptide,  p7-15,  as the target  antigen. 
In the mouse, insulin occurs in two related forms, desig- 
nated mouse insulin  I and II (30).  The primary sequences 
of both forms are shown in Fig.  5 in comparison with BI 
which was used as the antigen in this study. Of the 51 residues 
which comprise both the A and B chains, both forms of mu- 
fine  insulin  differ  from  the  bovine  sequence by only  six 
residues, and mouse insulin I differs from mouse insulin  II 
in two residues, a Pro to Set change at position 9, and a Lys 
to Met change at position 29 in the B chain.  Thus the in- 
sulin B chain p7-15 primary sequence in mouse insulin  II 
is identical to that of BI, and the mouse insulin I form differs 
by a single Set to Pro substitution  at position 9.  Since all 
individuals of the murine species express both insulin I and 
II, both forms are "recognized" by the immune  system as 
self-proteins. Thus the BIB chain p7-15 chymotryptic frag- 
ment, which serves as the target antigen for these B6-derived 
CTLs, is an autologous peptide, at least with respect to that 
found in the mouse insulin  II form. 
CTL Recognition of Insulin B  Chain p7-I5 Is H-2K  b Re- 
stricted.  To further characterize the B6-derived CTLs which 
respond to the insulin B chain peptide p7-15 on syngeneic 
target cells,  we sought to identify the specific  H-2  b mole- 
cule which serves as the restriction element for this response. 
Using L  cell fibroblast lines  transfected with  class  I  H-2  b 
genes as target cells, we assessed whether the p7-15-specific 
CTLs could respond to the insulin chymotryptic digest and 
insulin B chain p7-15 in the context of the D b and K b dass 
I molecules. As shown in Fig.  6, CTL recognition of this 
insulin peptide by the B6-derived CTL clone 10.5.4 is dearly 
restricted  to  the  H-2K  b class  I  molecule.  This  is demon- 
strated by the strong lytic response against transfected bK  b 
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Figure 6.  Response  of clone 10.5.4 
against  LK  b transfected  targets  in the 
presence of 4 #M (Q -  -  -  l)denatu~t 
insulin digest and (￿9 -  -  -  ￿9  insulin 
8 chain peptide, p7-I5; and against LD  b 
transfected  targets  in  the  presence  of 
(O  O)  denatured  insulin digest 
and (A  A) insulin B chain peptide, 
p7-15. 
target cells in the presence of both denatured insulin digest 
and the synthetic p7-15 antigens and by the lack of such re- 
sponse  on  transfected  L-D  b target  cells. The bulk  CTL 
effectors, from which clone 10.5.4 is derived, exhibit the same 
class I MHC restriction in the presence of this peptide (data 
not shown). 
Determination o.I the Minimal Antigenic Peptide Derived  jrom 
Insulin B Chain, p7-15.  To identify the minimal peptide neces- 
sary for CTL recognition, we synthesized various truncated 
peptides derived from the insulin B chain chymotryptic  frag- 
ment to determine the influence of individual residues in this 
sequence to H-2Kb-restricted CTL recognition. The results 
of this analysis are shown in Table 1. They reveal that removal 
of the amino acid residues Cys  ?, Gly  s, and Ser  9, from the 
amino-end of p7-15 has no effect on CTL recognition since 
peptides p8-15, p9-15, and p10-15 are undiminished in their 
antigenicity with respect to recognition by these B6-derived 
CTLs. The effect of removing the carboxyl-terminal Leu res- 
idue at position 15, however, results in abrogation of CTL 
recognition as indicated by the lack of CTI:mediated lysis 
in the presence of either p9-14 or p10-14. Thus, from this 
analysis, we conclude that the minimal antigenic sequence 
Table  1.  Determination of Minimum Antigenic Peptide 
Reactivity for Clone B6.BL10.5.4 
Peptide*  Sequence  CTL  reactivity* 
p7-15  C-G-S-H-L-V-E-A-L  58 
p8-15  G-S-H-L-V-E-A-L  55 
p9-15  S-H-L-V-E-A-L  54 
p10-15  H-L-V-E-A-L  55 
pl1-15  L-V-E-A-L  3 
p9-14  S-H-L-V-E-A  2 
p10-14  H-L-V-E-A  3 
*  All peptides were tested for antigenic activity at a final concentration 
of 2 #M in a 3-h StCr-release assay with stCr-labeled EL4 target cells. 
* Clone B6.BI-10.5.4  cells were used at an E/T ratio of 30:1. 
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Figure 7.  Peptide  competition on EL4 targets with clone 10.5.4 effectors: 
in both A and B ￿9  denotes the response against titrated concentrations 
from 4 #M to 5 nM of insulin  B chain peptide p7-15; and A, the response 
against p7-15 in the presence of 10 #M concentration of VSV N protein 
peptide p49-59. Clone 10.5.4 cells were used at a 10:1 E/T ratio. (A) 
(@), Titration of p7-15 response in the presence of 10/~M p10-14 trun- 
cated insulin B chain peptide; O, lytic response to 10 #M concentration 
of p10-14; (B) (I), Titration of p7-15 response in the presence of 10/~M 
pl1-15 truncated insulin B chain peptide;  [-3, lyric response to 10/~M 
concentration of p11-15. 
of the chymotryptic  fragment, p7-15, is His-Leu-Val-Glu-Ala- 
Leu, which comprises the insulin B chain peptide, p10-15. 
This core antigenic  peptide does not include the Pro~Ser 
sequence difference between mouse insulin I and BI at res- 
idue 9 (see Fig. 5). Thus, the sequence p10-15 of the target 
antigen is an autologous peptide in both forms of mouse in- 
sulin, and the B6-derived CTLs that are responsive to this 
peptide  may be considered autoreactive CTLs. 
To evaluate the contribution of individual residues in this 
peptide to MHC/peptide binding or TCR/peptide contact, 
we initiated  peptide  competition studies  using  an  excess 
amount (10 #M) of truncated peptides, which were not anti- 
genic with respect to CTL lysis of EL4 target cells, added 
together with titrated quantities of p7-15 (from 4 #M-5 nM). 
As a control for peptide/MHC binding, we used the vesic- 
ular  stomatitis  virus  (VSV) nuclear  (N)  protein peptide, 
p49-59, which has been shown previously to be a target an- 
tigen for lysis by Kb-restricted,  VSV-specific CTLs  (31). 
Using the antigenic peptide, p7-15, as the target antigen for 
CTL-mediated lysis we tested the inactive truncated peptides, 
p10-14 (Fig. 7 A) and p11-15 (Fig. 7 B), for competition 
of p7-15 peptide binding to L+K  b target cells. The results 
shown in Fig. 7 demonstrate that the addition of 10 #M VSV 
N protein p49-59 peptide, which fails to target lysis by the 
insulin  peptide-specific CTLs,  inhibits  the CTL  response 
against insulin  B chain p7-15.  This suggests that VSV N 
protein p49-59 binds  to the class I H-2K  b molecule in a 
manner such that it inhibits binding of the insulin B chain 
p7-15. However, addition of excess  insulin B chain truncated 
peptides p10-14 and pl1-15,  derived by the removal of Leu  ts 
and  His 1~ residues  respectively, failed to  inhibit  the  K  b- 
restricted  CTL lysis of EL4 target cells in the presence of 
antigenic peptide p7-15. Indeed, particularly in the presence 
of the p10-14 peptide, there appears to be some increase in 
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p7-15 peptide. These.findings indicate that removal of either 
Leu  15 or His 1~ abrogates peptide binding to the K b molecule. 
Currently we are evaluating each of the residues in the min- 
imal antigenic core peptide, p10-15,  with respect to their 
classification  as H-2Kb-binding residues or TCR-interacting 
residues. 
Discussion 
To examine the antigenicity of insulin with respect to a 
class I H-2-restricted CTL response, we have induced insulin 
peptide-specific CTLs from C57BL/6  (H-2  b) mouse spleen 
cells by in vitro stimulation with a chymotryptic digest of 
BI. The CD8 § CTLs induced in this manner, as described 
in this study, are specific for an autologous peptide derived 
from the B chain of the insulin molecule. In contrast to the 
results described in this paper, peptides from both the A and 
the B chain of insulin have been shown to be antigenic in 
the class II-restricted Th response to insulin. Furthermore, 
Delovitch and co-workers (5, 32, 33) have demonstrated that 
major epitopes for Th recognition of insulin are represented 
by the branched peptides, A1-14/B7-15, A1-14/B7-16, and 
A1-14/B7-26, which are comprised of peptide fragments from 
both the A  and B chains of insulin connected by an inter- 
chain disulfide bond between residues A7 and B7. In another 
report (8) it was demonstrated that the Th response to an 
insulin A chain-derived peptide could be inhibited by an in- 
sulin B chain peptide, p17-26.  Thus far we have failed to 
identify class I H-2-restricted T  cells,  specific for either A 
chain or branched peptides derived from both the A and B 
chains of insulin, from cultures of C57BL/6 spleen cells stimu- 
lated in vitro with chymotryptic digests of either reduced 
insulin or native, oxidized insulin. This may suggest that, 
under the conditions used in this study, the insulin B chain 
p7-15  chymotryptic fragment may be immunodominant, 
thereby preventing our detection of class I-restricted CTLs 
specific for branched peptides or peptides derived from the 
A chain. Indeed, CTLs specific for this same p7-15 insulin 
B chain fragment have emerged from several cultures induced 
in this manner. 
However, the antigenic peptide identified in this study is 
similar to a Th epitope of insulin B chain in C57BL/6 mice, 
p7-16,  reported by Jensen (9).  Recognition of this peptide 
by class II-restricted Th cells is dependent on the Cys  7 res- 
idue, as modification of this amino acid interferes with the 
antigenicity of the peptide. Our determination, in this study, 
of  insulin B chain-derived p10-15 as the minimal peptide neces- 
sary for targeting the antigen-specific lytic activity of these 
B6-derived CTLs, however, dearly rules out any influence 
on CTL recognition by not only the Cys  7 residue, but also 
by the Gly  s and Ser  9 residues of the B chain. Thus, to our 
knowledge, the CTL reactivity described in this study is unique 
with respect to T  cell recognition of insulin peptides, and 
furthermore, these results represent the first reported evidence 
of a class I MHC-restricted, insulin peptide-specific CTL re- 
sponse. 
Although the core antigenic peptide has been identified 
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as the hexamer, p10-15, it should be noted that the chymo- 
tryptic fragment responsible for induction of these insulin 
peptide-specific CTLs is the nonamer peptide, p7-15. In agree- 
ment with recent observations by several groups (31, 34-36), 
this peptide conforms to the proposed length of "naturally 
processed" peptides presented in the class I MHC presenta- 
tion pathway as being either nonamers or octamers. Thus, 
although the Cys  7, Gly  s, and Ser  9 residues are not required 
for Kb-restricted CTL recognition, they may be important 
for either appropriate processing or presentation in the class 
I pathway. Also worth noting is the predominantly hydro- 
phobic character of this Kb-presented peptide, which simi- 
larly is characteristic of the class II-presented insulin pep- 
tides (37).  As suggested by Lu et al.  (38),  the presence of 
recurrent hydrophobic residues in this CTL-recognized in- 
sulin peptide may be important to enable it to bind more 
efficiently to class I H-2K  b molecules, thereby increasing the 
likelihood that it will be expressed on the cell surface in a 
manner appropriate for T  cell recognition. The occurrence 
of hydrophobic residues at anchor positions two residues apart 
has also been identified in naturally processed peptides eluted 
from the K b molecule (36). 
The specificity of these H-2Kb-restricted CTLs for the au- 
tologous mouse insulin II B chain peptide, p7-15,  demon- 
strates that potentially autoreactive, insulin peptide-specific 
T cell receptors are expressed in the mature peripheral CD8 + 
T lymphocyte repertoire of the C57BL/6 mouse. That CTLs 
with this specificity can exist in the periphery, without any 
obvious detrimental effects to the insulin-producing pancreatic 
3  cells,  raises questions concerning their potential in vivo 
relevance. In this regard it should be considered that, in the 
present study, induction of these autoreactive CTLs may be 
dependent upon a Th epitope present in bovine insulin, but 
perhaps absent from murine insulin, which is exposed by in 
vitro digestion with ot-chymotrypsin. It is conceivable that 
activation  of an  insulin-responsive CD4 +  Th  population 
could provide a source for IL-2, which might be necessary 
for the induction and/or expansion of these potentially au- 
toreactive CD8 §  CTLs.  Indeed,  a  similar mechanism has 
been documented (39) for the expansion of CD8 + tumor- 
specific CTLs  by immunizing mice with cells from IL-2- 
secreting lines.  Thus the absence of this Th epitope in mu- 
rine  insulin  would  fail  to  activate  these  IL-2-producing 
CD4 + Th cells,  thereby precluding the expansion of this 
CD8 §  CTL population.  If this is the primary 
means of regulating this potentially autoreactive CTL popu- 
lation, then perhaps the induction and expansion of this popu- 
lation in vitro, as described in the present study, may over- 
come this requirement for CD4 § Th cells. 
Alternatively this potentially autoreactive CTL population 
may remain dormant in normal C57BL/6 mice due to the 
absence or low level of antigenic stimulation. Normal pan- 
creatic 3  cell metabolism results in the synthesis of proin- 
sulin followed by cleavage of the C peptide to yield the ma- 
ture form of insulin. This hormone is then secreted in its 
native, intact form. A  low level of insulin processing may 
occur through normal intracellular degradation in the pan- 
creatic 3 cells, thereby perhaps helping to maintain this dot- 
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We are presently investigating in diabetic NOD mice whether 
such an insulin-derived peptide, perhaps generated by abnormal 
metabolism in the diabetic pancreas,  may serve as  a target 
antigen for the activation of autoimmune CTL effectors in 
IDDM. 
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